Skip to main content

Table 3 Synthesis of main outcomes of the effect of bisphosphonates

From: Bisphosphonates as disease-modifying drugs in osteoarthritis preclinical studies: a systematic review from 2000 to 2020

Drug Reference C SB SM OST BM
Alendronate (n = 11) Adebayo et al. [38] ? + x ? x
Khorasani et al. [39] ? ? x +
Zhu et al. [31] ? + x x +
Mohan et al. [32] ? + x x ?
Panahafir et al. [33] + x x + x
Shirai et al., 2011 [23] + + x +
Zhang et al. [24] + + x x +
Sniekers et al. [40] + + x x x
Jones et al. [35] + + x + x
Ding et al. [42] + x x x
Hayami et al. [37] + + x + +
Zoledronic acid (n = 7) She et al. [20] + + x x x
Cinar et al. [29] + x + x
Bagi et al. [30] + x +
Lampropoulou et al. [21] + x x x x
Dearmin et al., 2014 [43] + x x +
Strassle et al. [36] + + ? x x
Muehleman et al., 2002 [28] + x x x +
Risedronate (n = 6) Permuy et al. [22] + + + x x
Thomsen et al. [41] ? x x +
Jones et al. [35] + + x x
MacNeil et al. [25] + + x x
Doschak et al. [26] + x x x
Doschak et al. [27] + x x
Tiludronate (n = 2) Moreau et al. [45] + + +
Pelletier et al. [44] + x x x +
Pamidronate (n = 1) Koh et al. [34] + + x x x
  1. C cartilage, SB subchondral bone, SM synovial membrane, OST osteophyte, BM biochemical markers. (+) Positive effect; (−) negative effect or no effect; (?) unclear effect; (x) not included